Takeda UK Ltd: NICE recommends LIVTENCITY? (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) refractory (with or without resistance) to prior therapies

Takeda UK Ltd. is pleased to announce that NICE has recommended the use of LIVTENCITY? (maribavir) as a twice daily oral treatment for adult patients with post-transplant cytomegalovirus (CMV)

Related Keywords

Australia ,Japan ,Canada ,United Kingdom ,London ,City Of ,British ,Rachel Miller ,El Chaer ,Anthony Nolan ,Peter Wheatley ,Mark Harber ,Simon Meadowcroft ,Maribavir Sm ,Drug Administration ,Prnewswire Takeda United Kingdom Ltd ,British Society Of Blood ,Regulatory Agency ,Takeda Pharmaceutical Company ,National Institute For Health ,Takeda Pharmaceutical Company Limited ,Takeda United Kingdom Ltd ,Takeda United Kingdom ,Transplanted Organ ,National Institute ,Care Excellence ,Final Appraisal Determination ,Marketing Authorisation ,Lead Nurse ,Consultant Nephrologist ,Royal Free London ,Country Medical Director ,Market Access ,Pricing Director ,United Kingdom Summary ,Product Characteristics ,Marketing Authorization ,European Economic Area ,Pharmaceutical Company Limited ,Plasma Derived Therapies ,Accessed December ,Health Utilization Cost ,Resistant Cytomegalovirus Infections ,Solid Organ Transplant Recipients ,Clinical Infectious Diseases ,Organ Donation ,Activity Report ,Accessed November ,British Society ,Marrow Transplantation ,Cellular Therapies ,Takeda ,Ice ,Ecommends ,Ivtencity ,Maribavir ,Treatment ,Adults ,Most ,Transplant ,Cytomegalovirus ,Refractory ,Without ,Resistance ,Rior ,Therapies ,